AbbVie

Phone: +18002555162

E-mail: abbviecontractmfg@abbvie.com, ebu.abv@abbvie.com

Web: https://www.abbvie.com

Type	Public company
Traded as	NYSE: ABBV S&P 100 component S&P 500 component
Industry	Biopharmaceutical
Founded	2013 (2013)
Headquarters	North Chicago, Illinois, U.S.
Area served	Worldwide (170+ countries)
Key people	Richard A. Gonzalez (Chairman and CEO) Michael Severino (Vice Chairman and President)
Products	Pharmaceutical drugs Humira (adalimumab) Imbruvica (ibrutinib) Venclexta (venetoclax) Zinbryta (daclizumab) Kaletra (lopinavir) Norvir (ritonavir) Mavyret/Maviret (glecaprevir/pibrentasvir) Skyrizi (risankizumab) Rinvoq (upadacitinib)
Revenue	US$56.20 billion (2021)
Operating income	US$17.92 billion (2021)
Net income	US$11.54 billion (2021)
Total assets	US$146.53 billion (2021)
Total equity	US$15.44 billion (2021)
Number of employees	50,000 (Jan 2022)
Website	abbvie.com

We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company. Our ~47,000 employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We come up with new approaches to addressing today’s health issues—from life-threatening illness to chronic conditions. We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We’re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies—and on science itself. At AbbVie, we see a future full of possibility, where health is in reach and patient lives are improved. See our employees, our science and our hope for tomorrow

For detailed contact information visit location pages below.